GILEAD SCIENCES, INC. (GILD) — SEC Filings

Latest SEC filings for GILEAD SCIENCES, INC. (GILD), explained in plain English.

Sentiment Overview: 42 neutral, 2 mixed

Recent Filings (44)

• 8-K Filing — 8-K · 2025-11-19T00:00:00.000Z [neutral]
• 13F-HR Filing — 13F-HR · 2025-11-13T00:00:00.000Z [neutral]
• Gilead Swings to Profit on Reduced R&D Impairments — 10-Q · 2025-11-07T00:00:00.000Z [mixed] Risk: medium
  Gilead Sciences, Inc. reported a significant turnaround in its financial performance for the nine months ended September 30, 2025, achieving a net income of $6.
• Gilead Sciences Files 8-K on Financials — 8-K · 2025-10-30T00:00:00.000Z [neutral] Risk: low
  Gilead Sciences, Inc. filed an 8-K on October 30, 2025, reporting on its results of operations and financial condition. The filing includes financial statements
• Gilead Sciences Files 8-K Report — 8-K · 2025-10-06T00:00:00.000Z [neutral] Risk: low
  On October 6, 2025, Gilead Sciences, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits. No
• 13F-HR Filing — 13F-HR · 2025-08-14T00:00:00.000Z [neutral]
• Gilead Sciences 8-K: Officer & Director Changes — 8-K · 2025-08-14T00:00:00.000Z [neutral] Risk: low
  Gilead Sciences, Inc. filed an 8-K on August 14, 2025, reporting events as of August 10, 2025. The filing covers the departure of directors or certain officers,
• Gilead's Q2 Sales Dip Amidst Steady Royalty Income — 10-Q · 2025-08-07T00:00:00.000Z [mixed] Risk: medium
  Gilead Sciences, Inc. reported product sales of $6.60 billion for the second quarter of 2025, a decrease from $6.70 billion in the second quarter of 2024. For t
• Gilead Sciences Files 8-K: Bylaws & Financials — 8-K · 2025-08-04T00:00:00.000Z [neutral] Risk: low
  Gilead Sciences, Inc. filed an 8-K on July 30, 2025, reporting amendments to its articles of incorporation or bylaws and filing financial statements and exhibit
• 13F-HR Filing — 13F-HR · 2025-05-13T00:00:00.000Z [neutral]
• Gilead Sciences Files 8-K on Shareholder Votes and Exhibits — 8-K · 2025-05-08T00:00:00.000Z [neutral] Risk: low
  Gilead Sciences, Inc. filed an 8-K on May 8, 2025, reporting on matters submitted to a vote of security holders and financial statements/exhibits as of May 7, 2
• Gilead Sciences Files Q1 2025 10-Q Report — 10-Q · 2025-05-07T00:00:00.000Z [neutral] Risk: low
  Gilead Sciences, Inc. filed its quarterly report on Form 10-Q for the period ending March 31, 2025. The filing details financial performance and operational upd
• Gilead Sciences Files 8-K on Financials — 8-K · 2025-04-24T00:00:00.000Z [neutral] Risk: low
  On April 24, 2025, Gilead Sciences, Inc. filed an 8-K report. The filing indicates that the report is primarily related to Results of Operations and Financial C
• DEF 14A Filing — DEF 14A · 2025-03-27T00:00:00.000Z [neutral]
• Gilead Sciences Announces Executive and Board Changes — 8-K · 2025-03-12T00:00:00.000Z [neutral] Risk: medium
  Gilead Sciences, Inc. announced on March 9, 2025, changes in its executive team and board of directors. The filing details the departure of certain officers and
• Gilead Sciences Files 2024 10-K — 10-K · 2025-02-28T00:00:00.000Z [neutral] Risk: medium
  Gilead Sciences, Inc. filed its 2024 10-K on February 28, 2025, reporting on its fiscal year ending December 31, 2024. The company, headquartered in Foster City
• 13F-HR Filing — 13F-HR · 2025-02-13T00:00:00.000Z [neutral]
• Gilead Sciences Files 8-K on Financials — 8-K · 2025-02-11T00:00:00.000Z [neutral] Risk: low
  On February 11, 2025, Gilead Sciences, Inc. filed an 8-K report to disclose information regarding its results of operations and financial condition. The filing
• Gilead Sciences Amends Officer and Director Filings — 8-K/A · 2024-12-13T00:00:00.000Z [neutral] Risk: low
  Gilead Sciences, Inc. filed an 8-K/A on December 13, 2024, to amend a previous filing from July 17, 2024. The amendment pertains to the departure of certain off
• Gilead Sciences Enters Material Agreement, Creates Financial Obligation — 8-K · 2024-11-20T00:00:00.000Z [neutral] Risk: medium
  On November 20, 2024, Gilead Sciences, Inc. entered into a material definitive agreement, likely related to financing or a significant transaction. This filing
• Gilead Sciences Files Q3 2024 10-Q — 10-Q · 2024-11-12T00:00:00.000Z [neutral] Risk: medium
  Gilead Sciences, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third qu
• Gilead Sciences Files 8-K on Financials — 8-K · 2024-11-06T00:00:00.000Z [neutral] Risk: low
  On November 6, 2024, Gilead Sciences, Inc. filed an 8-K report detailing results of operations and financial condition. The filing includes financial statements
• Gilead Sciences Files 10-Q for Q2 2024 — 10-Q · 2024-08-08T00:00:00.000Z [neutral] Risk: low
  Gilead Sciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results for the second quarter and the first half of th
• Gilead Sciences Announces Board and Executive Compensation Changes — 8-K · 2024-07-17T00:00:00.000Z [neutral] Risk: low
  Gilead Sciences, Inc. announced on July 17, 2024, changes in its board of directors and executive compensation. The filing details the departure of certain dire
• Gilead Sciences Files SC 13D/A for Assembly Biosciences — SC 13D/A · 2024-06-20T00:00:00.000Z [neutral] Risk: medium
  On June 20, 2024, Gilead Sciences, Inc. filed an amendment to its Schedule 13D concerning Assembly Biosciences, Inc. This filing indicates a change in beneficia
• Gilead Sciences Holds Annual Meeting, Elects Directors — 8-K · 2024-05-09T00:00:00.000Z [neutral] Risk: low
  On May 8, 2024, Gilead Sciences, Inc. filed an 8-K report detailing several key events. The company announced the results of its annual meeting of stockholders,
• Gilead Sciences Q1 2024 Update — 10-Q · 2024-05-08T00:00:00.000Z [neutral] Risk: medium
  Gilead Sciences, Inc. filed its quarterly report for the period ending March 31, 2024. The company reported key financial figures and provided updates on its bu
• Gilead Sciences Files SC 13D/A Amendment for Galapagos NV — SC 13D/A · 2024-05-02T00:00:00.000Z [neutral] Risk: medium
  Gilead Sciences, Inc. filed an amendment (No. 3) to its Schedule 13D on April 30, 2024, regarding its holdings in Galapagos NV. The filing indicates a change in
• Gilead Sciences Files 8-K on Financials — 8-K · 2024-04-25T00:00:00.000Z [neutral] Risk: low
  Gilead Sciences, Inc. filed an 8-K on April 25, 2024, reporting on its results of operations and financial condition, as well as filing financial statements and
• SC 13G Filing — SC 13G · 2024-04-19T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-04-05T00:00:00.000Z [neutral]
• Gilead Sciences DEF 14A: Executive Pay & Governance Details — DEF 14A · 2024-03-28T00:00:00.000Z [neutral] Risk: low
  Gilead Sciences, Inc. filed its DEF 14A on March 28, 2024, detailing executive compensation and corporate governance matters for the fiscal year ending December
• Gilead Sciences Files 8-K Report — 8-K · 2024-03-22T00:00:00.000Z [neutral] Risk: low
  On March 22, 2024, Gilead Sciences, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Reg
• Gilead Sciences Announces Executive and Board Changes — 8-K · 2024-03-14T00:00:00.000Z [neutral] Risk: low
  Gilead Sciences, Inc. announced on March 10, 2024, changes in its executive leadership and board of directors. The company elected two new directors, Dr. Debora
• Gilead Sciences Files 2023 10-K, Details Biological Products Focus — 10-K · 2024-02-23T00:00:00.000Z [neutral] Risk: medium
  Gilead Sciences, Inc. filed its 10-K on February 23, 2024, for the fiscal year ended December 31, 2023. The filing indicates the company's continued operation a
• SC 13G Filing — SC 13G · 2024-02-20T00:00:00.000Z [neutral]
• Vanguard Amends Gilead Sciences Stake, Holds 90.8M Shares — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral] Risk: low
  The Vanguard Group, a major investment firm, filed an amendment (SC 13G/A) on February 13, 2024, updating its ownership in Gilead Sciences Inc. As of December 2
• Gilead Sciences Updates Passive Stake in Tango Therapeutics — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral] Risk: low
  Gilead Sciences, Inc. filed an amended SC 13G/A on February 13, 2024, indicating its ownership of Tango Therapeutics, Inc. common stock as of December 31, 2023.
• Gilead Files 8-K on Material Definitive Agreement, Other Events — 8-K · 2024-02-12T00:00:00.000Z [neutral] Risk: medium
  Gilead Sciences, Inc. filed an 8-K on February 12, 2024, reporting an "Entry into a Material Definitive Agreement" and "Other Events" that occurred on February
• Capital World Investors Updates GILD Stake to 83.7M Shares — SC 13G/A · 2024-02-09T00:00:00.000Z [neutral] Risk: low
  Capital World Investors, a major institutional investor, has updated its holdings in Gilead Sciences, Inc. (GILD) as of December 29, 2023. The filing shows they
• Gilead Files 8-K on Financial Results & Condition — 8-K · 2024-02-06T00:00:00.000Z [neutral]
  Gilead Sciences, Inc. filed an 8-K on February 6, 2024, to report its financial results and condition, as well as to include related exhibits. This filing, unde
• Gilead Reports Officer Comp/Director Changes on Feb 1 — 8-K · 2024-02-02T00:00:00.000Z [neutral]
  Gilead Sciences, Inc. filed an 8-K on February 2, 2024, reporting an event that occurred on February 1, 2024. This filing indicates a change in compensatory arr
• Gilead Amends Arcus Biosciences Stake, Signals Ownership Change — SC 13D/A · 2024-01-31T00:00:00.000Z [neutral]
  Gilead Sciences, Inc. filed an amended Schedule 13D on January 31, 2024, updating its beneficial ownership in Arcus Biosciences, Inc. This amendment, triggered
• BlackRock Amends Gilead Sciences Stake (13G/A) — SC 13G/A · 2024-01-24T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended Schedule 13G/A on January 24, 2024, indicating its ownership of Gilead Sciences Inc. common stock as of December 31, 2023. This